- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Immunotherapy Advances in SCLC Highlight Promise, Limitations, and Biomarker Needs
November 15th 2025, 8:49pm
PER® New York Lung Cancer Symposium
Christine Hann, MD, PhD, discusses how recently presented SCLC data inform treatment decision-making across the LS-SCLC and ES-SCLC settings.
Dr Marron on the Evolving Role of Tarlatamab in SCLC
November 15th 2025, 8:36pm
PER® New York Lung Cancer Symposium
Thomas Marron, MD, PhD, discusses how findings from the DeLLphi-303 trial are shaping the use of tarlatamab across treatment settings in small cell lung cancer.
Dr Bhora on How Perioperative Immunotherapy Is Reshaping the Treatment Paradigm in Resectable NSCLC
November 15th 2025, 8:32pm
PER® New York Lung Cancer Symposium
Faiz Bhora, MD, FACS, discusses how data from the CheckMate 816, KEYNOTE-091, and AEGEAN trial have transformed perioperative therapy in resectable NSCLC.
Frontline STK-012 Plus Pembrolizumab and Chemo Shows Early Promise in PD-L1–Negative NSCLC
November 9th 2025, 11:00am
STK-012 plus pembrolizumab and chemotherapy showed early efficacy and manageable safety in PD-L1–negative NSCLC.
Dr Jänne on Key Areas of Ongoing Debate in EGFR+ NSCLC
October 30th 2025, 8:08pm
Bridging the Gaps in Lung Cancer
Pasi A. Jänne, MD, PhD, discusses key areas of debate in lung cancer management, with a focus on defining the optimal duration of adjuvant targeted therapy.
Dr Le on Innovations and Future Directions for KRAS Inhibition in NSCLC
October 30th 2025, 8:06pm
Bridging the Gaps in Lung Cancer
Xiuning Le, MD, PhD, discusses the current landscape of KRAS G12C inhibitors and emerging strategies for optimizing KRAS inhibition in NSCLC.
Advances in EGFR+, HER2-Mutant, and CNS-Involved NSCLC Dominate Discussion After ESMO 2025
October 30th 2025, 2:00pm
Experts highlight pivotal data in EGFR- and HER2-mutant NSCLC from the 2025 ESMO Congress, including updates on ADCs, TKIs, and real-world outcomes in LMD.
ESMO 2025 GI Cancer Data Highlight Emerging Precision Strategies and Treatment Avenues for Rare Cancers
October 30th 2025, 12:00pm
Revisit the most intriguing GI cancer data from the 2025 ESMO Congress.
Frontline Darovasertib Plus Crizotinib Shows Clinical Efficacy in Metastatic Uveal Melanoma
October 28th 2025, 2:04pm
Darovasertib plus crizotinib improved OS to 21.1 months and boosted response rates in first-line metastatic uveal melanoma vs historical approaches.
VERITAC-2 PRO Data Support Potential of Vepdegestrant in ESR1-Mutated ER+ Advanced Breast Cancer
October 28th 2025, 1:23pm
Vepdegestrant maintained QOL and reduced risk of symptom deterioration vs fulvestrant in ESR1-mutated ER-positive, HER2-negative advanced breast cancer.
ESMO 2025 Breast Cancer Data May Redefine Treatment Standards Across Patient Subgroups
October 27th 2025, 1:00pm
Revisit the top data and presentations in breast cancer from the 2025 ESMO Congress.
Perioperative Durvalumab Plus FLOT Generates OS Benefit in Gastric/GEJ Adenocarcinoma
October 26th 2025, 10:00am
Saruparib plus an androgen receptor pathway inhibitor was safe and active in metastatic prostate cancer.
ctDNA Clearance With Adjuvant Therapy Is Associated With Improved DFS in CRC
October 25th 2025, 10:00am
Adjuvant therapy was associated with ctDNA clearance and improved DFS in patients with resectable stage I to IV CRC.
Saruparib Plus an ARPI Shows Activity, Tolerability in Metastatic Prostate Cancer
October 24th 2025, 12:00pm
Saruparib plus an androgen receptor pathway inhibitor was safe and active in metastatic prostate cancer.
Cadonilimab Plus Chemo Retains Clinically Meaningful Survival Advantage in Frontline Gastric/GEJ Adenocarcinoma
October 23rd 2025, 1:00pm
First-line cadonilimab plus chemotherapy demonstrated long-term efficacy benefits vs chemotherapy alone in patients with advanced gastric or GEJ adenocarcinoma.
Trastuzumab Rezetecan Displays PFS Benefit Vs Pyrotinib Plus Capecitabine in Pretreated HER2+ Breast Cancer
October 23rd 2025, 12:00pm
Trastuzumab rezetecan reduced the risk of disease progression or death by 78% vs pyrotinib plus capecitabine in pretreatedHER2+ advanced breast cancer,
Atezolizumab Plus BCG Does Not Improve EFS Vs BCG Alone in BCG-Naive NMIBC
October 22nd 2025, 12:00pm
Atezolizumab plus BCG did not extend EFS vs BCG alone in BCG-naive, high-risk non–muscle invasive bladder cancer.
Pinpointing Pivotal Prostate Cancer Data With Drs Agarwal and Shore
October 21st 2025, 8:00pm
OncLive News Network: On Location at ESMO 2025
Neeraj Agarwal, MD, FASCO, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in prostate cancer presented during the 2025 ESMO Congress.
Buparlisib Plus Paclitaxel Fails to Yield OS Benefit in PD-1/PD-L1–Pretreated HNSCC
October 21st 2025, 2:03pm
ESMO Congress: Head and Neck Cancer
Buparlisib plus paclitaxel did not show an improvement in OS vs paclitaxel alone in PD-1/PD-L1–pretreated recurrent/metastatic HNSCC.
Alternative Docetaxel Regimen Plus Darolutamide/ADT Lowers Toxicity in mHSPC
October 21st 2025, 12:00pm
A reduced docetaxel regimen helped lower rates of AEs when combined with daolutamide and ADT in mHSPC.